Diamyd Medical AB: Ten Percent Screened In European Phase III Study Of Diamyd(R) Diabetes Vaccine

STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Diamyd Medical (Pink Sheets:DMYDY)(STO:DIAMB): Ten percent of the children participating in the European phase III study have been screened and about a dozen have received their first injection.